HopeStage
Back to all studies
CompletedNCT01720095

Niaspan Added to Antipsychotics for Thinking Skills After First-Episode Psychosis

About this titleRead the official source — NCT01720095
Medication studyAges 18–35CanadaSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 35 years.

Listed locations
HalifaxSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2009
Recruitment status
Completed
Enrollment listed in the registry
22
Sponsor
Nova Scotia Health Authority
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 18 Years to 35 Years
Official registry ID
NCT01720095
Official title
Show the full official title

A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Halifax

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Nova Scotia Health Authority.

Did this study involve medication?

Yes. The study involved medication, including Niaspan.

Who was this study for?

Listed age limits: 18 years to 35 years.

Want to explore more studies?

Explore studies